Overview

Study to Assess Drug Levels and Safety of Golcadomide (BMS-986369) in Healthy Participants and Participants With Different Degrees of Hepatic Impairment

Status:
RECRUITING
Trial end date:
2025-10-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the drug levels and safety of golcadomide (BMS-986369) in adult participants with moderate and severe Hepatic Impairment (HI), and in matched healthy control participants with normal hepatic function.
Phase:
PHASE1
Details
Lead Sponsor:
Celgene